EAE in UBC-CreERT2 and Foxp3-CreERT2 mice with induced deletion of CTLA-4
| Clinical EAE | Histological EAE | ||||||
| Parameters | Incidence | Day of onset | Mean maximal score | Incidence | Meningeal foci | Parenchyma foci | Total foci |
| Mean ± SE | Mean ± SE | Mean ± SE | Mean ± SE | Mean ± SE | |||
| UBC−Cre− (all) | 41/49 (83.7%) | 13.9 ± 0.4 | 2.2 ± 0.4 | 11/11 (100%) | 55.5 ± 13.9 | 69.5 ± 23.5 | 125.2 ± 36.9 |
| UBC-Cre+ (sunflower oil) | 5/5 (100%) | 13.0 ± 0.7 | 3.5 ± 0.2 | 4/4 (100%) | 106 ± 11.8 | 99.8 ± 12.8 | 205.8 ± 23.2 |
| UBC−Cre+ (tamoxifen) | 16/44 (36.4%) | 14.1 ± 1.0 | 0.4 ± 0.3 (P < 0.0001)a | 12/13 (92.3%) | 10.2 ± 3.8 (P = 0.003) | 5.5 ± 2.3 (P = 0.007) | 15.6 ± 5.7 (P = 0.004) |
| Foxp3−Cre− CTLA-4fl/fl | 7/8 (87.5%) | 11.9 ± 0.5 | 2.9 ± 0.5 | ||||
| Foxp3−Cre+ CTLA-4+/+ | 2/2 (100%) | 10.5 ± 0.5 | 3.3 ± 0.8 | ||||
| Foxp3−Cre+ CTLA-4fl/+ | 12/13 (92.3%) | 12.0 ± 1.1 | 2.7 ± 0.3 | ||||
| Foxp3−Cre+ CTLA-4fl/fl | 2/16 (12.5%) | 14.0 ± 4.0 | 0.3 ± 0.2 (P < 0.0001) | ||||
| Clinical EAE | Histological EAE | ||||||
| Parameters | Incidence | Day of onset | Mean maximal score | Incidence | Meningeal foci | Parenchyma foci | Total foci |
| Mean ± SE | Mean ± SE | Mean ± SE | Mean ± SE | Mean ± SE | |||
| UBC−Cre− (all) | 41/49 (83.7%) | 13.9 ± 0.4 | 2.2 ± 0.4 | 11/11 (100%) | 55.5 ± 13.9 | 69.5 ± 23.5 | 125.2 ± 36.9 |
| UBC-Cre+ (sunflower oil) | 5/5 (100%) | 13.0 ± 0.7 | 3.5 ± 0.2 | 4/4 (100%) | 106 ± 11.8 | 99.8 ± 12.8 | 205.8 ± 23.2 |
| UBC−Cre+ (tamoxifen) | 16/44 (36.4%) | 14.1 ± 1.0 | 0.4 ± 0.3 (P < 0.0001)a | 12/13 (92.3%) | 10.2 ± 3.8 (P = 0.003) | 5.5 ± 2.3 (P = 0.007) | 15.6 ± 5.7 (P = 0.004) |
| Foxp3−Cre− CTLA-4fl/fl | 7/8 (87.5%) | 11.9 ± 0.5 | 2.9 ± 0.5 | ||||
| Foxp3−Cre+ CTLA-4+/+ | 2/2 (100%) | 10.5 ± 0.5 | 3.3 ± 0.8 | ||||
| Foxp3−Cre+ CTLA-4fl/+ | 12/13 (92.3%) | 12.0 ± 1.1 | 2.7 ± 0.3 | ||||
| Foxp3−Cre+ CTLA-4fl/fl | 2/16 (12.5%) | 14.0 ± 4.0 | 0.3 ± 0.2 (P < 0.0001) | ||||
Data in Clinical EAE are pooled from seven independent experiments (four with UBC−CreERT2 mice and three with Foxp3−CreERT2 mice) in which EAE was induced by immunization with 150 µg MOG35-55 subcutaneously, and administration of 250 ng pertussis toxin intraperitoneally on the day of immunization and two days later. Mice with no disease were included in calculations of maximal score, but excluded from calculations of day of disease onset.
All p-values are compared with Cre− control.